GENE News | Stock Alarm Pro

Atlas News Feed Alerts PortfolioEconomy Movers Regime Earnings Updates

GENE(GENE)

GENE

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Stock Alarm Pro

Real-time monitoring, screening, and research for professional investors and financial advisors.

support@stockalarm.io

Product

Screener
Chart Studio
Alerts
Institutional
Atlas

Company

About
For advisors
Blog
Press
Contact

© 2026 Stock Alarm, LLC, a product of Center Mark Capital, LLC. Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

Home Screener Alerts

GENE 5 articles

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

benzinga.com·Aug 3

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

benzinga.com·May 18

Genetic variations linked to weight loss, side effects from GLP-1 drugs

reuters.com·Apr 10

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

benzinga.com·Jul 30

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

accessnewswire.com·Jun 18

GENE(GENE)

$0.77—

GENE(GENE)

NASDAQ

$0.77—